Medine.co.uk

Drontal Plus Xl Flavour Tablets For Dogs

Revised: November 2013

AN: 00387/2012

SUMMARY OF PRODUCT CHARACTERISTICS


1. NAME OF THE VETERINARY MEDICINAL PRODUCT


Drontal Plus XL Flavour Tablets for Dogs


2. QUALITATIVE AND QUANTITATIVE COMPOSITION



Each tablet contains:


mg per tablet


Febantel


Pyrantel embonate


Praziquantel

525.0


504.0


175.0





Excipients




Artificial beef flavour Irradiated

408.0


For the full list of excipients, see section 6.1


3. PHARMACEUTICAL FORM


Tablet.

Pale brown to brown oval shaped divisibletablet scored on both sides.


4. CLINICAL PARTICULARS


4.1 Target species


Dogs.


4.2 Indications for use, specifying the target species


For the control of the following roundworms and tapeworms in adult dogs:


Ascarids:

Toxocara canis, Toxascaris leonina (adult and late immature forms).


Hookworms:

Uncinaria stenocephala, Ancylostoma caninum (adults)


Whipworms:

Trichuris vulpis (adults)

Tapeworms:

Echinococcus spp. Taenia spp. and Dipylidium caninum (adult and immature forms).


4.3 Contraindications

Do not use simultaneously with piperazine compounds.


4.4 Special warnings for each target species


Fleas serve as intermediate hosts for one common type of tapeworm -Dipylidium caninum. Tapeworm infestation is certain to re-occur unless control of intermediate hosts such as fleas, mice etc. is undertaken.


Since it contains praziquantel, the product is effective against Echinococcus multilocularis,which does not occur in the UK or Ireland but is becoming more common in some European countries. As a precautionary measure to prevent establishment of E multilocularisin the UK and Ireland, it is recommended that all dogs entering the country be treated with praziquantel.


4.5 Special precautions for use


i) Special precautions for use in animals


Any part-used tablets should be discarded.

Do not exceed the stated dose when treating pregnant bitches.


ii) Special precautions to be taken by the person administering the medicinal product to animals


In case of accidental ingestion, seek medical advice and show package leaflet to the physician.


In the interests of good hygiene, persons administering the tablet directly to a dog or by adding it to the dog’s food, should wash their hands afterwards.


4.6 Adverse reactions (frequency and seriousness)


None known.


4.7 Use during pregnancy and lactation


Consult a veterinary surgeon before treating pregnant animals for roundworms.

Drontal Plus XL Flavour Tablets may be used during lactation (see Section 4.9 below).


4.8 Interaction with other medicinal products and other forms of interaction

Do not use simultaneously with piperazine.

Concurrent use with other cholinergic compounds is not recommended.


4.9 Amount(s) to be administered and administration route

Dosage


The recommended dose rates are: 15 mg/kg bodyweight febantel,

14.4 mg/kg pyrantel and 5 mg/kg praziquantel. This is equivalent to 1 tablet per 35 kg bodyweight as follows:


Dosages are as follows:


Body weight (kg)

Tablet quantity

17.5

½

>17.5 - 35

1

>35 - 52.5

1 ½

>52.5 - 70

2


Drontal Plus Flavour Tablets should be used to achieve accurate dosing in dogs weighing less than 17.5 kg. The dose is equivalent to 1 tablet per 10 kg.


Administration and Duration of Treatment


Oral administration: the tablet(s) can be given directly to the dog or disguised in food. No starvation is needed before or after treatment.


For routine treatment a single dose is recommended.


For the control of Toxocara, nursing bitches should be dosed 2 weeks after giving birth and every 2 weeks until weaning.


For routine control adult dogs should be treated every 3 months. In the event of a heavy roundworm infestation, a repeat dose should be given after 14 days.


4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary


Drontal Plus XL Flavour Tablets are well tolerated in dogs. In safety studies doses of 5 x or greater gave rise to occasional vomiting.


4.11 Withdrawal period(s)


Not applicable.


5. PHARMACOLOGICAL PROPERTIES


Pharmacotherapeutic group:

Anthelmintics, tetrahydropyrimidine


ATC VetCode: QP52AF30

The product contains anthelmintics active against roundworms and tapeworms. The product contains three active substances:


Febantel, a pro-benzimidazole.

2) Pyrantel embonate (pamoate), a tetrahydropyrimidine derivative, and

3) Praziquantel, a partially hydrogenated pyrazino-isoquinoline derivative.


5.1 Pharmacodynamic Properties


In this fixed combination product pyrantel and febantel act synergistically against relevant nematodes (ascarids, hookworms and whipworms) in dogs. In particular, the activity spectrum covers Toxocara canis, Toxascaris leonina, Uncinaria stenocephala, Ancylostoma caninum and Trichuris vulpis.


The spectrum of activity of praziquantel covers all important cestode species in dogs, in particular all Taenia spp, Dipylidium caninum, Echinococcus granulosus and Echinococcus multilocularis. Praziquantel acts against adult and immature forms of these parasites.


Praziquantel is very rapidly absorbed and distributed throughout the parasite. Both in vivo and in vitro studies have shown that praziquantel causes severe damage to the parasite integument, resulting in contraction and paralysis. There is an almost instantaneous tetanic contraction of the parasite musculature and a rapid vacuolisation of the syncytial tegument. This rapid contraction has been explained by changes in divalent cation fluxes, especially calcium.


Pyrantel acts as a cholinergic agonist. Its mode of action is to stimulate nicotinic cholinergic receptors of the parasite, induce spastic paralysis and thereby allow removal from the gastro-intestinal (GI) system by peristalsis.


Within the mammalian system febantel undergoes ring closure forming fenbendazole and oxfendazole. It is these chemical entities which exert the anthelmintic effect by inhibition of tubulin polymerisation. Formation of microtubules is thereby prevented, resulting in disruption to structures vital to the normal functioning of the helminth. Glucose uptake, in particular, is affected, leading to a depletion in cell ATP. The parasite dies upon exhaustion of its energy reserves, which occurs 2-3 days later.


5.2 Pharmacokinetic Properties


No data available.


6. PHARMACEUTICAL PARTICULARS


6.1 List of excipients


Artificial beef flavour Irradiated

Maize starch

Lactose monohydrate

Microcrystalline cellulose

Povidone K25

Magnesium stearate

Sodium laurilsulfate

Silica colloidal anhydrous


6.2 Incompatibilities


None known.


6.3 Shelf-life


Shelf-life of the veterinary medicinal product as packaged for sale: 3 years.


6.4 Special precautions for storage


Do not store above 25ºC.

Any part used tablets should be discarded


6.5 Nature and composition of immediate packaging


Container material:

PCTFE/PVC-aluminium foil strip


Container colour:

White


Container sizes:

Cartons containing 2, 8, 48 and 96 tablets

Not all pack sizes may be marketed.


Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products, if appropriate


Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.


7. MARKETING AUTHORISATION HOLDER


UK Only:

IE Only:

Bayer plc,

Animal Health Division,

Bayer House,

Strawberry Hill,

Newbury,

Berkshire RG14 1JA

Bayer Ltd,

Animal Health Division,

The Atrium,

Blackthorn Road,

Dublin 18,

Ireland


8. MARKETING AUTHORISATION NUMBERS


UK Only:

IE Only:

Vm 00010/4153

VPA 10021/55/1


9. DATE OF FIRST AUTHORISATION


UK Only:

IE Only:

31 March 2008

20 March 2009


10. DATE OF LAST REVISION OF THE TEXT


UK Only:

IE Only:

November 2013

TBC


APPROVED 28/11/2013